Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 against Fusarium clinical isolates: focus on voriconazole and amphotericin B
Authors:
Open Access
- 1 September 2026
- journal article
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5)
Abstract
Objectives: Despite the global emergence of Fusarium infections, data validating commercial antifungal susceptibility testing against these moulds remain scarce. We evaluated the performance and optimal reading time of the Sensititre YeastOne (SYO) assay against Fusarium clinical isolates compared with the EUCAST reference method. Methods: This two-centre study (2011–2023) analysed 123 Fusarium isolates identified via two-step molecular sequencing. In vitro susceptibilities to voriconazole and amphotericin B were evaluated using SYO (24 h and 48 h readouts) versus the EUCAST E.Def 9.4 broth microdilution reference method (48 h readout). Essential agreement (EA) was defined as a ±2 log2 dilution difference; >90% was acceptable. Results: Fusarium solani species complex (FSSC) dominated the cohort (85.3%), predominantly F. keratoplasticum and F. pseudensiforme. EUCAST testing revealed high MIC50/MIC90 values of voriconazole (>16/>16 mg/L) and amphotericin B (2/16 mg/L). While 65% (80/123) of isolates displayed positivity by SYO at 24 h, median spectrophotometric growth was significantly greater at 48 h than at 24 h [0.37 (IQR 0.315–0.403) versus 0.18 (0.151–0.206)]. At 48 h, EA approached acceptability for voriconazole (92.7%) and amphotericin B (89.4%). Voriconazole categorical agreement (CA) among FSSC was 88.6% and reached 96.9% for F. pseudensiforme. For amphotericin B, SYO MICs clustered around 4–8 mg/L, yielding 100% very major error for F. keratoplasticum and F. pseudensiforme but 100% CA for F. falciforme, F. petroliphilum and non-FSSC. Conclusions: Voriconazole and amphotericin B susceptibility determined by SYO cannot universally replace reference methods due to failure to detect non-WT to amphotericin B for prevalent species within FSSC. However, alongside accurate species-level molecular identification, SYO provides actionable susceptibility data for validated species-antifungal combinations.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (112-2314-B-002-143-MY3)
- National Health Research Institutes (IV-114-SP-09)
This publication has 24 references indexed in Scilit:
- Assessment of the molecular identification algorithm and its impact on antifungal susceptibilities against clinical Fusarium isolates: a multicentre study in Taiwan, 2011–2023JAC-Antimicrobial Resistance, 2026
- Clinical and Hospital Environmental Fusarium in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Phylogenetic AnalysesMycoses, 2025
- Neurovascular Complications of Iatrogenic Fusarium solani MeningitisNew England Journal of Medicine, 2024
- Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomesJournal of Antimicrobial Chemotherapy, 2023
- Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases PharmacistsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for MicrobiologyThe Lancet Infectious Diseases, 2021
- In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexesMycoses, 2021
- Do high MICs predict the outcome in invasive fusariosis?Journal of Antimicrobial Chemotherapy, 2020
- In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC DeterminationAntimicrobial Agents and Chemotherapy, 2020
- Inter-technique variability between antimicrobial susceptibility testing methods affects clinical classification of cefuroxime in strains close to breakpointClinical Microbiology and Infection, 2020